<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:8pt Arial, sans-serif; }
 .font2 { font:9pt Arial, sans-serif; }
 .font3 { font:21pt Arial, sans-serif; }
 .font4 { font:10pt Times New Roman, serif; }
 .font5 { font:17pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font5">J.P. Morgan</span></p>
<p><span class="font0" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font2" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font2" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font2" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font2" style="font-weight:bold;">isabella.zhao@jpmorgan.com</span></a></p><a name="caption1"></a>
<h3><a name="bookmark0"></a><span class="font3"><a name="bookmark1"></a>Investment Positives</span></h3>
<p><span class="font4" style="font-weight:bold;">Fully integrated healthcare empire with synergies from all value chain coverage</span></p>
<p><span class="font4">Fosun Pharmaceutical offers investors access to an integrated platform covering almost all subsectors along the healthcare value chain. For example, its manufacturing business distributes drugs through its distribution/hospitals channel. Its high-value/priced devices are sold at their hospitals. We believe it will continue to outperform the market with positive operating and financial synergies through:</span></p>
<ul style="list-style:none;"><li>
<p><span class="font4">1. &nbsp;&nbsp;&nbsp;Stable, growing pharmaceutical manufacturing business;</span></p></li>
<li>
<p><span class="font4">2. &nbsp;&nbsp;&nbsp;Expanding pharmaceutical distribution business with Sinopharm;</span></p></li>
<li>
<p><span class="font4">3. &nbsp;&nbsp;&nbsp;First mover advantage in private hospital industry with rapid expansion of network</span></p></li>
<li>
<p><span class="font4">4. &nbsp;&nbsp;&nbsp;Better product offerings in medical devices such as IVD and Da Vinci surgical robotic system</span></p></li></ul>
<p><span class="font1" style="font-weight:bold;">Table 1: Fosun’s Fully Integrated Business Model</span></p>
<p><span class="font2" style="font-weight:bold;">Fosun's Fully Integrated Business Covers Pharmaceutical Value Chain</span></p>
<table border="1">
<tr><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">R&amp;D and Manufacturing</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">Channel</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2" style="font-weight:bold;">End User</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Phaimaceutical Products</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Distribution</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Healthcare Services</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Metabolism, CV, CNS, Blood System, Anti-Infective, Oncology, API etc.</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Owns 27.84% equity interest in Sinopharm</span></p></td><td style="vertical-align:middle;">
<ul style="list-style:none;"><li>
<p><span class="font2" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;General hospitals: Yueyang Guang Gi, Suqian Zhongwu, Foshan Chan Cheng</span></p></li>
<li>
<p><span class="font2" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Specialty hospital: Anhui Jimin</span></p></li>
<li>
<p><span class="font2" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Premium Hospital United Family</span></p></li></ul></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Diagnostic products and Medical devices</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Medical devices distribution</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-weight:bold;">Phaimacy</span></p></td></tr>
<tr><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font2" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Biochemical diagnosis</span></p></li>
<li>
<p><span class="font2" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Gene diagnosis</span></p></li>
<li>
<p><span class="font2" style="font-weight:bold;">• &nbsp;&nbsp;&nbsp;Transfusion supplies</span></p></li></ul></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">Distribution through a variety of partners like MAKO, Intuitive surgical etc.</span></p></td><td style="vertical-align:top;">
<p><span class="font2" style="font-weight:bold;">• Over 3000 retail pharmacies</span></p>
<p><span class="font2" style="font-weight:bold;">• Largest retail pharmacy chain by sales in China</span></p></td></tr>
</table>
<p><span class="font0">Source: Company data, J.P. Morgan</span></p>
<p><span class="font4" style="font-weight:bold;">Rapidly expanding hospital network offers ample room for growth</span></p>
<p><span class="font4">Fosun was the pioneer of public hospital reform. It formed strategic cooperation with Chindex and entered China's premium private hospital market. Since then, Fosun has acquired five large hospitals both general and specialized. As of 1H2016, Fosun hospital revenue accounted for 11% of total revenue, up from merely Rmbl Imn or 0.2% of total revenue in 2011. Now Fosun has a total of 3,078 beds in operation and more than 6,300 beds under construction, which will gradually be in operation by 2018. Fosun usually acquires these hospitals at much lower valuation as they are non-profitable public hospitals. It aims to expand the number of beds in operation by a CAGR of 20% in 2016 to 2018 , implying significant topline contribution.</span></p>
<p><span class="font2" style="font-weight:bold;">6</span></p>
</body>
</html>